ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

1978-79 Budgets By Program Areas

June 3, 1977

Senate Commitee Approves $1.058 Trillion To Reverse Sequestration Cuts

June 21, 2013

In Brief: Senate approves $13.69 Billion for NIH, House To Act This Week; Amounts Are Close

September 19, 1997

NCI-Approved Clinical Trials

October 29, 2004

RFP: Intellectual Property.

March 31, 2000

Commemoration Planned For Heidelberger

February 11, 1983